FDA recall: sodium bicarbonate in 5% dextrose injection by SterRx

Aug. 12, 2021

SterRx is recalling three lots of sodium bicarbonate in 5% dextrose injection 150 mEq per 1,000 mL due to waterborne microbial contamination.

Intravenous administration of sodium bicarbonate in 5% dextrose injection 150 mEq per 1,000 mL, intended to be sterile that is not sterile, could result in site specific infections as well as serious systemic infections,  which may be life-threatening. To date, SterRx has not received reports of any adverse events associated with this issue.

Sodium bicarbonate injection is indicated for the following conditions:

  • High Potassium (Hyperkalemia)
  • Irregular heartbeat (QRS prolongation ex. tricyclic antidepressant poisoning)
  • Metabolic acidosis related to severe renal disease, uncontrolled diabetes, severe primary lactic acidosis, circulatory insufficiency due to shock, severe dehydration, extracorporeal circulation of blood, cardiac arrest, drug toxicities, barbiturates, salicylate, toxic alcohols, urine alkalization, severe diarrhea with HCO3 loss.

FDA Recall

ID 204561283 | Abstract © Dimitris Barletis | Dreamstime.com
dreamstime_xl_204561283
ID 366090882 © Zhanna Hapanovich | Dreamstime.com
dreamstime_xl_366090882
ID 179810040 © Josepalbert13 | Dreamstime.com
cdc_3
ID 150983874 © Adonis1969 | Dreamstime.com
dreamstime_xl_150983874
ID 241576013 © Josepalbert13 | Dreamstime.com
cms_2